Exercise in a Pill Is Now in Human Trials - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Exercise in a Pill Is Now in Human Trials

Atrogi's ATR-258 just dosed its first subjects — and the muscle data it's hunting could reframe how we treat weight loss.

  • By

  • Kerri Miller

  • March 18, 2026

  • 2 min

Share

Objective:

To evaluate the effects of ATR-258, a compound designed to replicate the metabolic benefits of exercise, in human subjects.

Approach:
    Key Findings:
    • Safety and tolerability were established in a previous Phase 1 trial with 69 subjects.
    • The current trial aims to gather data on muscle physiology, including biopsies and functional measures.
    Interpretation:

    ATR-258 targets muscle-sparing weight loss, addressing a gap left by GLP-1 treatments focused primarily on obesity.

    Limitations:
    • The study is limited to overweight men and has a narrow 8-week duration.
    • Generalizability and long-term metabolic outcomes are yet to be determined.
    Conclusion:

    ATR-258 could be significant in addressing muscle loss during weight loss, with results expected later this year.

    Sources:

Original Source(s)

Exercise in a Pill Is Now in Human Trials

  • by Kerri Miller

  • March 18, 2026

Related Content

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

Upfront Cost Guidance Limited in US Guidelines

Although most large US-based medical societies in a cross-sectional study explicitly suggested considering economic or resource use–related evidence during guideline development, only 3.8% of individual recommendations included that information in the recommendation statement itself.

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.